Form D · Pharmaceuticals
ADIAL PHARMACEUTICALS, INC.
Glen Allen, VA · CIK 0001513525
Offering snapshot reported Dec 3, 2025 · SEC filing
- Reported sold
- $4.29M Offering amount: $4.29M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 28, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 3, 2025 | Initial | $4,285,289 | No comparison | 1 | SEC filing |
| May 14, 2025 | Initial | $4,815,379 | No comparison | 1 | SEC filing |
| Mar 14, 2024 | Initial | $287,500 | No comparison | 1 | SEC filing |
| Oct 26, 2023 | Initial | $3,998,582 | No comparison | 1 | SEC filing |
| Jun 5, 2023 | Initial | $52,500 | No comparison | 1 | SEC filing |
| Mar 6, 2023 | Initial | $61,603 | No comparison | 1 | SEC filing |
| Feb 17, 2022 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Jul 12, 2021 | Initial | $500,004 | No comparison | Not reported | SEC filing |
| Mar 26, 2021 | Initial | $291,003 | No comparison | 5 | SEC filing |
| Nov 30, 2020 | Initial | $295,750 | No comparison | 1 | SEC filing |
| Sep 25, 2020 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Jun 17, 2020 | Initial | $5,217,000 | No comparison | 6 | SEC filing |
| Jun 14, 2018 | Initial | $325,000 | No comparison | 1 | SEC filing |
| Mar 13, 2018 | Initial | $500,000 | No comparison | 7 | SEC filing |
| Dec 5, 2017 | Initial | $100,000 | No comparison | 5 | SEC filing |
| Aug 31, 2017 | Initial | $40,000 | No comparison | 2 | SEC filing |
| May 16, 2017 | Initial | $287,500 | No comparison | 1 | SEC filing |
| Oct 2, 2013 | Initial | $2,631,042 | No comparison | 35 | SEC filing |
| Mar 16, 2011 | Initial | $4,100,000 | No comparison | 0 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $229K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-565667
Consists of $0.31 per share that may be received upon future exercise of warrants to purchase up to 13,823,512 shares of common stock.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| A.G.P./Alliance Global Partners | 000005361 |
Source: Form D, filed Dec 3, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James K. Anderson | Director |
| Robert S Capon | Director |
| Cary J. Claiborne | Director, Executive |
| Robertson H. Gilliland | Director |
| Tony Goodman | Director, Executive |
| Bankole A. Johnson | Executive |
| Mike L King | Director |
| Ming D. Li | Director |
| Leonard Meyer | Director |
| James W. Newman, Jr. | Director |
| Jack W. Reich | Director |
| John F Riccardi | Director, Executive |
| Kevin Schuyler | Director |
| Kevin W. Schuyler, Cfa | Director |
| Vinay Shah | Executive |
| William B Stilley | Director, Executive |
| W Illiam Stilley | Executive |
| William B. Stilley, Iii | Director, Executive |
| Joseph M. Truluck | Executive |
| Wendy L Yarno | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4870 Sadler Road Suite 300
Glen Allen, VA, 23060
Phone: (804) 487-8196
Glen Allen, VA, 23060
Phone: (804) 487-8196